#biotech

🏢Release 📈 Stocks

Genmab Shares Rally as Petosemtamab Trial Cuts Death Risk by 50%

October 28, 2026 (13 days ago)

Genmab's petosemtamab combination therapy significantly improved survival rates in a Phase 3 head and neck cancer trial, meeting dual primary endpoints and…

GMAB

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Novo Nordisk Presents New MASH Data for Wegovy at AASLD Conference

October 28, 2026 (13 days ago)

Novo Nordisk shares new clinical data for Wegovy in MASH treatment, utilizing the PLATINUM-Truveta analysis to benchmark performance against resmetirom and other…

NVO MDGL AKRO

🌍 EUROPE Read More →

🏢Release 📈 Stocks

ExpreS2ion Biotech Proposes 62.6M SEK Capital Reduction at Dec 1 EGM

October 28, 2026 (13 days ago)

ExpreS2ion Biotech will hold an EGM on December 1, 2026, to vote on a technical capital reduction and amendments to the company's…

EXPRS2

🌍 EUROPE Read More →

🏢Release 📈 Stocks — 📊 Neutral

Biologics Development: Optimizing Potency Assay Strategies for Quality

October 28, 2026 (13 days ago)

This webinar examines how strategic potency assays provide essential measures of biological function and quality throughout the lifecycle of biologics development.

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

MetaVia Presents Phase 1 Clinical Trial Data for DA-1726 at Symposium

October 28, 2026 (13 days ago)

MetaVia Inc. shares Phase 1 clinical trial data for its novel dual oxyntomodulin candidate DA-1726, advancing its pipeline for the treatment of…

MTVA

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Micron Biomedical Appoints Former Lilly and AstraZeneca Executive to Lead

October 28, 2026 (13 days ago)

Micron Biomedical strengthens its leadership team with a veteran executive from Lilly and AstraZeneca to drive global product development and commercialization efforts.

Micron Biomedical

🌍 AMERICAS Read More →

🏛️Filing 📈 Stocks

Senti Biosciences Reports Board and Executive Leadership Changes

October 27, 2026 (13 days ago)

Senti Biosciences discloses executive and board-level leadership changes in its latest 8-K filing, marking a significant shift in the company's corporate governance…

SNTI

🌍 US Read More →

🏢Release 📈 Stocks

Cardiff Oncology Appoints Interim CMO to Lead Clinical Development

October 27, 2026 (13 days ago)

Cardiff Oncology strengthens its leadership team with a new interim Chief Medical Officer tasked with accelerating the development of its cancer treatment…

CRDF

🌍 AMERICAS Read More →

🏛️Filing 📈 Stocks

Senti Biosciences Files 8-K Disclosing Asset Disposition and Equity Sales

October 26, 2026 (14 days ago)

Senti Biosciences reports a material agreement termination and asset disposition alongside unregistered equity sales, raising concerns over corporate restructuring and shareholder dilution.

SNTI

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Natural Field Shifts Strategy Toward Advanced Delivery Tech at SupplySide 2026

October 26, 2026 (15 days ago)

Natural Field pivots to advanced delivery systems and science-backed formulations at SupplySide Global 2026, signaling a shift toward higher-value product development in…

Natural Field

🌍 ASIA Read More →

🏢Release 📈 Stocks

Genmab Reports 28.2 Months Median Survival in Phase 2 Head and Neck Cancer Trial

October 26, 2026 (15 days ago)

Genmab's petosemtamab combination therapy shows strong efficacy in Phase 2 trials for head and neck cancer, achieving a 28.2-month median overall survival…

GMAB

🌍 EUROPE Read More →

🏢Release 📈 Stocks

DropGenie Secures $5 Million Seed+ Funding to Scale Functional Biology Platform

October 26, 2026 (15 days ago)

DropGenie secures $5 million in Seed+ funding to scale its functional biology platform, enabling broader access to patient-derived cell data for discovery…

DropGenie

🌍 AMERICAS Read More →